Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose

The aim of this study was to evaluate the detection efficiency of 111In-PSMA-I&T SPECT/CT in comparison to hybrid 68Ga-PSMA HBED-CC PET in patients with early recurrent prostate cancer.

Methods

Twenty-two patients (mean age, 68.2 ± 6.8 years; range, 52–76 years) with rising prostate-specific antigen (PSA; median, 1.03 ng/mL; range, 0.2–7.2ng/mL) and known positive lesions in hybrid 68Ga-PSMA HBED-CC PET scheduled for salvage surgery were included. Whole-body scintigraphy and SPECT/CT were performed 4 hours after application of 147.0 ± 24.8 MBq (range, 90–183 MBq) 111In-PSMA I&T. Images were evaluated for suspected lesions, and conspicuity of all lesions was rated using a 4-point-scale (0 = not seen, 1 = retrospectively seen in knowledge of 68Ga-PSMA HBED-CC PET, 2 = low signal, 3 = high signal). Tumor-to-background ratios were determined for SPECT and PET and compared. Tumor-to-background ratio of SPECT was correlated with lesion size as well as patients’ Gleason score and PSA level.

Results

111In-PSMA I&T SPECT/CT detected 14 of 29 PET-positive lesions (48.3%) with no additional lesions identified with 111In-PSMA I&T SPECT/CT. There was a significant weak to moderate correlation of PSA level with tumor-to-background ratio of 111In-PSMA I&T SPECT/CT (correlation coefficient r = 0.6406; 95% confidence interval, 0.1667–0.8741; P = 0.0136). There was no significant difference (P > 0.05), but a weak trend toward a higher detectability in 111In-PSMA I&T SPECT/CT regarding lesion size and initial PSA level.

Conclusions

In a preselected collective of recurrent prostate cancer patients with low PSA values, 111In-PSMA I&T SPECT/CT showed lower detection rates than hybrid 68Ga-HBED-CC PSMA PET. However, 111In-PSMA I&T SPECT/CT showed a patient based detection rate of 59%, making it a potentially valuable imaging tool where PET is not available apart from its proven value as a PSMA-targeted probe for radioguided surgery.

Related Topics

    loading  Loading Related Articles